PPBT vs PRME

Purple Biotech Ltd. vs Prime Medicine, Inc. — Valuation Comparison 2026

PPBT

Biotechnology
Purple Biotech Ltd.
Quality
3.6
out of 10
Value Trap
Price
$2.81
Last close
Models
2/13
Active
VS

PRME

Biotechnology
Prime Medicine, Inc.
Quality
5.1
out of 10
Value Trap
26
LOW
Price
$3.40
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType PPBT Fair ValuePPBT Upside PRME Fair ValuePRME Upside
Bayesian DCF Intrinsic $0.85 -75.0%
EROIC Spread Intrinsic $1.34 -52.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.54 -80.7% $0.82 -75.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PPBT vs PRME — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PPBT vs PRME — Which Stock Is More Undervalued?

PRME scores higher with a 5.1/10 quality rating vs PPBT's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Purple Biotech Ltd. (PPBT) and Prime Medicine, Inc. (PRME) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PPBT currently trades at $2.81 with a QOC of 3.6/10, while PRME trades at $3.40 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).